Online inquiry

IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1446MR)

This product GTTS-WQ1446MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Aβ15-42 gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3579MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ8494MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ3291MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ10930MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ2081MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ11638MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ1243MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ15317MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW